Urogen pharma ltd. (URGN)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Dec'16
Assets
CURRENT ASSETS:
Cash and cash equivalents

26,468

49,688

66,147

90,424

246,692

101,318

109,483

119,109

127,460

36,999

21,362

Marketable securities

92,623

97,389

92,046

98,739

-

-

-

-

-

-

-

Restricted cash

1,223

523

523

307

407

253

197

197

197

198

95

Short-term investments

-

-

-

-

-

-

-

-

-

36,001

-

Accounts receivable

-

-

-

-

-

-

112

232

4

-

83

Inventory

-

-

-

-

-

-

-

142

349

316

105

Prepaid expenses and other current assets

1,552

1,034

1,160

1,724

1,196

672

1,679

1,024

726

958

396

TOTAL CURRENT ASSETS

121,866

148,634

159,876

191,194

248,295

102,243

111,471

120,704

128,736

74,472

22,041

NON-CURRENT ASSETS
Property and equipment, net

991

977

893

909

929

948

992

718

637

805

741

Restricted deposit

223

223

55

55

51

51

81

80

29

29

24

Right of use asset

3,433

3,735

-

-

-

-

-

-

-

-

-

Marketable securities

40,137

48,555

63,506

43,851

-

-

-

-

-

-

-

Other non-current assets

279

264

2,423

2,557

2,777

317

14

-

-

244

250

TOTAL ASSETS

166,929

202,388

226,753

238,566

252,052

103,559

112,558

121,502

129,402

75,550

23,056

Liabilities and Shareholder's equity
CURRENT LIABILITIES:
Accounts payable and accrued expenses

8,500

11,186

7,880

7,071

5,942

8,540

6,291

5,655

4,048

4,435

1,880

Employee related accrued expenses

4,075

6,711

5,082

3,706

3,334

4,925

2,684

2,211

1,291

1,950

687

Other current liabilities

1,632

1,585

1,126

1,067

1,001

-

-

-

-

-

-

Deferred revenues

-

-

-

-

-

-

-

86

196

650

-

Proceeds from exercise of warrants for preferred shares

-

-

-

-

-

-

-

-

-

-

570

TOTAL CURRENT LIABILITIES

14,207

19,482

14,088

11,844

10,277

13,465

8,975

7,952

5,535

7,035

3,137

NON-CURRENT LIABILITIES:
Long-term lease liability

2,268

2,604

1,749

1,943

2,184

-

-

-

-

-

-

TOTAL NON-CURRENT LIABILITIES

-

-

1,749

1,943

2,184

-

-

-

-

-

-

TOTAL LIABILITIES

16,475

22,086

15,837

13,787

12,461

13,465

8,975

7,952

5,535

7,035

6,749

Warrants for preferred shares

-

-

-

-

-

-

-

-

-

-

3,612

COMMITMENTS AND CONTINGENCIES (Note 14)

-

-

-

-

-

-

0

0

-

-

0

SHAREHOLDERS’ EQUITY:
Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at March 31, 2020 and December 31, 2019; 21,212,940 and 21,026,184 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

58

57

57

57

56

44

44

43

42

37

6

Additional paid-in capital

415,895

407,986

399,600

391,233

383,850

212,921

202,693

192,129

184,421

115,692

43,502

Accumulated deficit

-265,800

-228,000

-189,000

-166,800

-144,315

-122,900

-99,154

-78,622

-60,596

-47,214

-27,214

Accumulated other comprehensive income

311

276

303

281

-

-

-

-

-

-

-

TOTAL SHAREHOLDERS’ EQUITY

150,454

180,302

210,916

224,779

239,591

90,094

103,583

113,550

123,867

68,515

16,307

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

166,929

202,388

226,753

238,566

252,052

103,559

112,558

121,502

129,402

75,550

23,056